Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis-Reference-Cited by-同舟云学术

Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis

Published:2019-10-14 Issue:14 Volume:20 Page:1447-1460
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

Parizadeh Seyed Mostafa¹,Jafarzadeh-Esfehani Reza²,Ghandehari Maryam¹,Hasanzadeh Malihe³,Parizadeh Seyed Mohammad Reza¹,Hassanian Seyed Mahdi¹,Rezaei-Kalat Afsaneh⁴,Aghabozorgi Amirsaeed Sabeti⁵,Rahimi-Kakhki Rana¹,Zargaran Bita¹,Ferns Gordon A⁶,Avan Amir¹

Affiliation:

1. Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Iran

2. Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3. Department of Gynecology Oncology, Woman Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4. Department of Psychiatry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5. Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

6. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, United Kingdom

Abstract

Ovarian cancer (OC) is one of the most common cancers globally with a high rate of cancer- associated mortality. OC may be classified into epithelial cell neoplasms, germ cell neoplasms and stromal cell neoplasms. The five-year survival in the early and advanced stages of disease is approximately 90% and 15%, respectively. microRNAs are short, single-stranded, non-coding ribonucleic acid (RNA). miRNAs play critical roles in post transcriptionally regulations of gene expression. miRNAs are found in different tissues and body fluids. In carcinogenesis the expression of miRNAs are altered. Recent studies have revealed that there is a relationship between alteration of miRNAs expression and the prognosis of patients with OC. The aim of this review was to summarize the findings of recent studies that have investigated the expression of circulating and tissue miRNAs as novel biomarkers in the prognosis of OC.

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Reference159 articles.

1. Ferlay J.; Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC cancerbase GLOBOCAN 2000.2001

2. Reid B.M.; Permuth J.B.; Sellers T.A.; Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017,14(1),9-32

3. Artioli G.; Borgato L.; Ausoni S.; Azzarello G.; Ovarian cancer: BRCA genetics reveals targets for new therapies. J Genet Syndr Gene Ther 2014,5(1),1

4. Stratton J.F.; Pharoah P.; Smith S.K.; Easton D.; Ponder B.A.; A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998,105(5),493-499

5. Jessmon P.; Boulanger T.; Zhou W.; Patwardhan P.; Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther 2017,17(5),427-437

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of albumin-lymphocyte score and skeletal muscle index predicts prognosis of ovarian patients after primary debulking surgery: A multicenter retrospective study;2024-05-16

2. Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer;International Journal of Molecular Sciences;2023-09-28

3. The polymorphism rs4705342 in the promoter of miR-143/145 is related to the risk of epithelial ovarian cancer and patient prognosis;Frontiers in Oncology;2023-04-04

4. Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer;Biomedicines;2022-12-02

5. Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer;Gynecologic Oncology Reports;2022-02